Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 · New England Journal of Medicine · 903 citations
https://doi.org/10.1056/nejmoa2302983
S
Shugeng Gao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
206
Papers
6.3K
Citations
38
h-index
103
i10-index
Shugeng Gao is an academic researcher from Tongji University. The author has contributed to research in topics: Lung Cancer Diagnosis and Treatment & Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers. The author has an h-index of 38, co-authored 176 publications.
ORCID: 0000-0003-4211-552XPapers by this author
worksNeoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
2020 · Journal of Thoracic Oncology · 399 citations
https://doi.org/10.1016/j.jtho.2020.01.017
The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
2020 · European Journal of Nuclear Medicine and Molecular Imaging · 87 citations
https://doi.org/10.1007/s00259-020-04711-3
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection
2022 · Molecular Cancer · 81 citations
https://doi.org/10.1186/s12943-022-01594-w
Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma
2022 · EBioMedicine · 74 citations
https://doi.org/10.1016/j.ebiom.2022.104281
Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma
2020 · Nature Communications · 59 citations
https://doi.org/10.1038/s41467-020-18702-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat